Abstract
The understanding of cytokine networks and the exploitation of these networks for the treatment of immune and inflammatory diseases as well as cancer depend on in vivo delivery of cytokines. Due to instability of recombinant cytokine proteins, investigators have employed cytokine-encoding gene therapy vectors to induce high levels of cytokine expression in vivo. Numerous gene therapy vectors have been developed recently which are suitable for this purpose. Recent advances in the design of adenovirus, adeno-associated virus, poxvirus, retrovirus, lentivirus, and nonviral vectors are described here. Properties of the various vector systems which determine their usefulness for cytokine gene delivery are compared. The implementations of cytokine-encoding gene therapy vectors for analyzing immune responses and for the therapy of inflammatory disorders, immune disease, infections and cancer are reviewed.
Keywords: Gene Vectors, Cytokine Exprssion, Recombinant, Cancer, Immune, Inflammatory Diseases, adenovirus, Poxvirus, retrovirus, lentivirus, nonviral vectors, gene regulation, Transcription, RNA, Molecular Biology, Wild Type, EIA, ITRs, dCMP, Poxviral, Vaccinia, Retroviral, Leukemia, CD4, MLV, Lentiviral, Pro Inflammatory Matory Vectors, Coxsackie adenovirus receptor, Serotype 2, Murine leukemia, Granulocyte macrophage colony stimulatin, Interleukin, Transforming growth, interferon, Tumor necrosis, Helper T cell, Dendritic
Current Pharmaceutical Design
Title: Gene Vectors for Cytokine Expression In Vivo
Volume: 6 Issue: 6
Author(s): M. M. Hitt and J. Gauldie
Affiliation:
Keywords: Gene Vectors, Cytokine Exprssion, Recombinant, Cancer, Immune, Inflammatory Diseases, adenovirus, Poxvirus, retrovirus, lentivirus, nonviral vectors, gene regulation, Transcription, RNA, Molecular Biology, Wild Type, EIA, ITRs, dCMP, Poxviral, Vaccinia, Retroviral, Leukemia, CD4, MLV, Lentiviral, Pro Inflammatory Matory Vectors, Coxsackie adenovirus receptor, Serotype 2, Murine leukemia, Granulocyte macrophage colony stimulatin, Interleukin, Transforming growth, interferon, Tumor necrosis, Helper T cell, Dendritic
Abstract: The understanding of cytokine networks and the exploitation of these networks for the treatment of immune and inflammatory diseases as well as cancer depend on in vivo delivery of cytokines. Due to instability of recombinant cytokine proteins, investigators have employed cytokine-encoding gene therapy vectors to induce high levels of cytokine expression in vivo. Numerous gene therapy vectors have been developed recently which are suitable for this purpose. Recent advances in the design of adenovirus, adeno-associated virus, poxvirus, retrovirus, lentivirus, and nonviral vectors are described here. Properties of the various vector systems which determine their usefulness for cytokine gene delivery are compared. The implementations of cytokine-encoding gene therapy vectors for analyzing immune responses and for the therapy of inflammatory disorders, immune disease, infections and cancer are reviewed.
Export Options
About this article
Cite this article as:
Hitt M. M. and Gauldie J., Gene Vectors for Cytokine Expression In Vivo, Current Pharmaceutical Design 2000; 6 (6) . https://dx.doi.org/10.2174/1381612003400551
DOI https://dx.doi.org/10.2174/1381612003400551 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design Melanoma: Prognostic Factors and Factors Predictive of Response to Therapy
Current Medicinal Chemistry Derivatives of Procaspase-Activating Compound 1 (PAC-1) and their Anticancer Activities
Current Medicinal Chemistry Cell-penetrating Peptide-mediated Nanovaccine Delivery
Current Drug Targets Oncolytic Virus Therapy - Foreword
Current Cancer Drug Targets Withdrawal Notice: Recent Developments in Anti-Cancer Activity of Compounds Containing the Thioether Group
Anti-Cancer Agents in Medicinal Chemistry Insights on the Neuromodulatory Propensity of Selaginella (Sanjeevani) and its Potential Pharmacological Applications
CNS & Neurological Disorders - Drug Targets Clinical Relevance of Cytokines and Inflammatory Molecules in Rheumatoid Vasculitis
Current Rheumatology Reviews Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Mini-Reviews in Medicinal Chemistry Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry The Asymmetric [C+NC+CC] Coupling Reaction: Development and Application to Natural Product Synthesis
Current Organic Synthesis Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry Nanotechnology in Cancer Therapy: Targeting the Inhibition of Key DNA Repair Pathways
Current Molecular Medicine Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Anal Carcinoma
Current Cancer Therapy Reviews Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular Carcinoma Tumorigenesis
Current Pharmaceutical Design Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design